☢️Synthesized Clinical Bottom Line Updated 11-16-2025 The provided collection of research, which includes three major Phase 3 randomized controlled trials (RCTs), supplies strong evidence for the de-escalation of radiation therapy in several common breast cancer settings. The central, unifying theme is that the survival benefits historically attributed to radiation have been substantially or entirely negated […]
Comment: This SEER data review of T1-2N1 breast cancer patients continues the trend we’ve been observing: Postmastectomy Radiotherapy (PMRT) rarely translates into a statistically significant survival advantage in the modern setting. After adjusting for selection bias using Propensity Score Matching (PSM), the 5-year Breast Cancer-Specific Survival (BCSS) was comparable between the PMRT and non-PMRT groups. […]
📝 Comment: This trial provides a critical, high-level confirmation: modern systemic therapy has fundamentally changed the risk/benefit profile of post-mastectomy chest-wall irradiation (CWI) for intermediate-risk breast cancer. The key takeaway is that for the overall population, a minimal absolute reduction in local recurrence (less than 2 percentage points) did not translate into an Overall Survival […]
Comment: This 10-year follow-up of the PRIME II trial reinforces a crucial point for managing older patients with low-risk, hormone-positive breast cancer. Yes, omitting radiotherapy after breast-conserving surgery increased the 10-year local recurrence rate significantly (from 0.9% to 9.5%). However, the definitive, practice-changing finding is that this 10-fold increase in local recurrence had zero impact on […]
